Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) is a clinical-stage gene therapy pioneer developing innovative treatments for ocular and rare diseases through its proprietary intravitreal platform. This resource provides investors and medical professionals with essential updates on the company's clinical trials, regulatory milestones, and strategic initiatives.
Access real-time information about ADVM's AAV-based therapies designed to reduce treatment burdens in conditions like wet AMD. The page aggregates official press releases, partnership announcements, and trial result disclosures - critical data for evaluating the company's progress in advancing durable single-dose therapies.
Key content includes updates on lead candidates like the wet AMD gene therapy program, manufacturing developments, and peer-reviewed research publications. Track progress across therapeutic areas including ophthalmology and rare genetic disorders through verified company communications.
Bookmark this page for streamlined access to ADVM's latest scientific advancements and corporate updates. Check regularly for new developments in their mission to transform chronic disease management through groundbreaking gene therapy approaches.
Adverum Biotechnologies (ADVM) reported positive interim data from its OPTIC Phase 1 clinical trial of ADVM-022, a gene therapy for wet age-related macular degeneration (AMD). The data indicate long-term durability beyond 15 months post-single injection, with a robust treatment response and a significant reduction in the need for anti-VEGF rescue injections. Financially, cash reserves stood at $280.1 million as of June 30, 2020, enabling operation funding into 2022. However, the company recorded a net loss of $29.2 million for the second quarter, reflecting increased R&D and administrative expenses.
Adverum Biotechnologies (Nasdaq: ADVM) announced a conference call on August 10, 2020, at 1:30 pm PT to discuss its Q2 2020 financial results and provide a corporate update. This call will focus on the company's gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema. Investors can access the live webcast through the company's website and are encouraged to join 15 minutes early for the call.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Thomas Kochy as vice president of commercial and program strategy. This new position focuses on leading commercial planning and product strategy. Kochy brings over 15 years of experience in the biopharmaceutical industry, notably in ophthalmology at Genentech. He holds an MBA from the University of California, Berkeley. As part of his onboarding, Kochy received a stock option to purchase 100,000 shares of ADVM's common stock.
The company is advancing clinical trials for its gene therapy candidate ADVM-022.
Adverum Biotechnologies (Nasdaq: ADVM) has randomized the first patient in the INFINITY clinical trial to evaluate ADVM-022 for diabetic macular edema (DME). DME affects about 5% of individuals with diabetes, a condition impacting over 30 million people in the U.S. The INFINITY trial aims to assess the effectiveness of a single injection of ADVM-022 compared to standard therapy. With the goal of reducing treatment burden, the company expects to present data from the trial in the second half of 2021. This advancement highlights Adverum's commitment to addressing significant unmet medical needs in vision loss therapies.
Adverum Biotechnologies (Nasdaq: ADVM) announced the completion of patient dosing in Cohort 4 of the OPTIC Phase 1 trial for ADVM-022, aimed at treating wet age-related macular degeneration (AMD). This trial involves a single intravitreal injection designed to reduce dependence on frequent anti-VEGF treatments. The trial’s primary focus is on safety and tolerability, with preliminary data suggesting significant long-term benefits from the therapy. Adverum plans to release comprehensive results from all cohorts by the end of 2020, potentially transforming treatment paradigms for wet AMD.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Heikki Jouttijärvi as vice president of manufacturing effective June 25, 2020. He will lead the manufacturing and supply chain strategy, reporting to CTO Angela Thedinga. Jouttijärvi has over 25 years of global pharmaceutical experience and was previously VP at Menlo Therapeutics. He received a stock option for 100,000 shares as an inducement. This leadership change aims to bolster manufacturing capabilities as Adverum progresses its gene therapy candidate ADVM-022 through clinical trials.
Adverum Biotechnologies (Nasdaq: ADVM) has appointed Dr. Laurent Fischer as CEO, succeeding Leone Patterson, who remains President. Dr. Fischer brings over 20 years of biopharmaceutical experience, having previously held senior positions at Allergan and Tobira Therapeutics. This leadership change aims to enhance the development of ADVM-022, a gene therapy targeting wet age-related macular degeneration and diabetic macular edema. The board is optimistic about leveraging Fischer's expertise to optimize growth and patient outcomes.
Adverum Biotechnologies (Nasdaq: ADVM) announced the initiation of the INFINITY Phase 2 trial for ADVM-022, targeting diabetic macular edema (DME), the leading cause of vision loss in diabetic retinopathy. This randomized, controlled trial will enroll approximately 33 patients to evaluate the efficacy of a single intravitreal injection of ADVM-022 compared to aflibercept. The company also reported Q1 2020 financials, with a net loss of $22.9 million and cash reserves of $297.1 million, expected to fund operations into 2022. Positive interim data from the OPTIC Phase 1 trial for wet AMD was presented, with full cohort results anticipated by year-end.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) will host a conference call on May 28, 2020, at 1:30 PM PT to discuss its Q1 2020 financial results and business updates. The call will be accessible via audio webcast on the company's website. Participants are encouraged to dial in 15 minutes early. Adverum is focused on addressing unmet medical needs in ocular and rare diseases, particularly with its gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) released positive interim data from the OPTIC Phase 1 trial of ADVM-022 for treating wet age-related macular degeneration (AMD). Key findings include strong efficacy with zero rescue injections in Cohort 1 over one year and encouraging results in Cohort 3, with significant improvements in vision and anatomy. The company reported $297 million in cash as of March 31, 2020, and plans to begin patient enrollment for diabetic retinopathy trials later this year. A conference call will elaborate on these findings.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
